IRLAB Therapeutics Logo

IRLAB Therapeutics

IRLAB | XSTO

Overview

Corporate Details

ISIN(s):
SE0012675361 (+1 more)
LEI:
549300JAT34LHEI0DH60
Country:
Sweden
Address:
Arvid Wallgrens backe 20, 413 46 Göteborg
Sector:
Health Care
Industry:
Biotechnology

Description

Rooted in Nobel Prize-winning research, IRLAB has grown rapidly to become recognized and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders and especially Parkinson’s disease. We have a well-defined, strategically focused R&D pipeline of powerful new treatments targeting the various stages of Parkinson’s as they worsen over time throughout the patient’s journey of neurodegeneration. Having a full range of effective disease management options for Parkinson’s patients is regarded as essential by both the medical and patient communities – and at the same time potentially a blockbuster pharmaceutical business.

Social Media

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-05-12 08:30
Declaration of Voting Results & Voting Rights Announcements
KALLELSE TILL ÅRSSTÄMMA I IRLAB THERAPEUTICS AB
Swedish 65.6 KB
2025-05-12 08:30
Regulatory News Service
Notice to the Annual General Meeting in IRLAB Therapeutics AB
English 38.5 KB
2025-05-07 07:00
Quarterly Report
Swedish 380.2 KB
2025-05-07 07:00
Quarterly Report
English 372.4 KB
2025-04-25 21:30
Annual Report
Swedish 10.2 MB
2025-03-05 13:40
Earnings Release
IRLAB reports topline results from a Phase IIb study of pirepemat in patients w…
English 54.9 KB
2025-03-05 13:40
Earnings Release
IRLAB rapporterar topline-resultat från en Fas IIb-studie med pirepemat i patie…
Swedish 56.8 KB
2025-02-18 00:20
Capital/Financing Update
IRLAB strengthens its value creation capabilities through extended and expanded…
English 52.2 KB
2025-02-18 00:20
Capital/Financing Update
IRLAB stärker sina möjligheter till värdeskapande genom förlängd och utökad lån…
Swedish 52.8 KB
2025-02-12 07:00
Annual Report
Swedish 371.1 KB
2025-02-12 07:00
Annual Report
English 716.7 KB
2024-11-21 15:30
Regulatory News Service
Valberedningen utsedd inför IRLAB:s årsstämma 2025
Swedish 41.7 KB
2024-11-21 15:30
Regulatory News Service
Nomination committee appointed for IRLAB’s annual general meeting 2025
English 41.0 KB
2024-07-10 07:00
Interim Report
Swedish 339.6 KB
2024-07-10 07:00
Interim Report
English 306.5 KB

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-05 Kristina Torfgård Other Buy 9,000 140,850.00 SEK
2024-08-05 Kristina Torfgård Other Buy 4,500 70,875.00 SEK
2024-05-14 Gunnar Olof Olsson Other Buy 2,000 31,000.00 SEK
2024-05-10 Daniel Johnsson Other Buy 20,000 259,680.00 SEK
2023-04-03 Joakim Tedroff Other Buy 51,430 2,038,685.20 SEK
2022-09-01 Richard Godfrey Other Buy 5,000 174,457.00 SEK
2022-08-30 Viktor Siewertz Other Buy 40 1,420.00 SEK
2022-08-29 Viktor Siewertz Other Sell 40 1,408.00 SEK
2022-07-15 Joakim Tedroff Other Other 84,148 N/A
2022-05-31 Viktor Siewertz Other Buy 4,500 170,370.00 SEK

Peer Companies

Company Country Ticker View
1NKEMIA Logo 1NKEMIA Spain IKM
2cureX AB Logo 2cureX AB Sweden 2CUREX
4SC AG Logo 4SC AG Germany VSC
Abera Bioscience AB Logo Abera Bioscience AB Sweden ABERA
ABIONYX Pharma Logo ABIONYX Pharma France ABNX
Abliva Logo Abliva Sweden ABLI
AB Science Logo AB Science France AB
Acticor Biotech Logo Acticor Biotech France ALACT
Active Biotech Logo Active Biotech Sweden ACTI
AcuCort AB Logo AcuCort AB Sweden ACUC